This article available in Chinese version only

港股成交昨創新高 續看好可留意港交牛51399/恒指購22369

2021-01-20 11:17:47

大市昨日迎來數宗好消息,恒指不但創逾一年半新高,整體市場成交亦超過三千億元,創歷來最高。北水昨日淨流入逾261億元人民幣,同是有紀錄以來新高,其中港交所(0388)為淨買入第二多,金額超過33億元。在成交增加及市場憧憬陸續有內地企業來港上市的支持下,港交所股價連番創新高昨見525元,即市升幅減半後今天再發力。投資者若續看好港交所股價,可留意牛證51399, 收回價 451.88 元, 2021年10月到期 ,實際槓桿 7.4 倍; 相反如看淡則可留意熊證63139, 收回價 542.88 元, 2021年12月到期 ,實際槓桿 14.1 倍。

 

恒指周一及周二累升逾1,068點後今天再接再厲,逼近三萬點大關。上日恒指淡倉有超過2.5億元資金淨流入,好倉牛證雖淨流出7,700萬元,但同時認購證淨吸約3,588萬元。恒指升,相關恒指波幅指數亦上升,投資者若續看好恒指及相關波動性,可留意認購證22369,行使價 31000 點, 2021年12月到期 ,實際槓桿 6.9 倍; 相反如看淡恒指可留意熊證67130, 收回價 30488 點, 2021年12月到期 ,實際槓桿 29.7 倍。

 

其他滙豐輪證焦點:

 

港交認購證29793,行使價 568.88 元, 2021年7月到期 ,實際槓桿 5.7 倍。

港交認沽證29409,行使價 398.88 元, 2021年7月到期 ,實際槓桿 6.7 倍。

港交牛證51399,行使價 449.38 元, 收回價 451.88 元, 2021年10月到期 ,實際槓桿 7.4 倍。

港交熊證63139,行使價 545.38 元, 收回價 542.88 元, 2021年12月到期 ,實際槓桿 14.1 倍。

 

恒指認購證22369,行使價 31000 點, 2021年12月到期 ,實際槓桿 6.9 倍。

恒指認沽證29392,行使價 26888 點, 2021年12月到期 ,實際槓桿 5.9 倍。

恒指牛證51476,行使價 28473 點, 收回價 28573 點, 2023年8月到期 ,實際槓桿 24.7 倍。

恒指熊證67130,行使價 30588 點, 收回價 30488 點, 2021年12月到期 ,實際槓桿 29.7 倍。

 

更新日期及時間: 2021年1月20日  上午10:15

Intrady newsletters
Back to Intrady newsletters
本結構性產品並無抵押品,如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。

本文由香港上海匯豐銀行有限公司(「本行」或「發行商」)發行(包括任何參考條款),僅供參考之用,並不構成邀約、游說、或建議出售或購買結構性產品。

結構性產品屬複雜產品,投資者務須就此審慎行事,除非投資者完全了解及願意承擔所涉風險,否則切勿投資此產品。結構性產品價格可急升可急跌,投資者或會損失所有或大部分投資。過往表現並不反映將來表現。投資前應了解結構性產品之性質及風險,並詳閱有關上市文件,獨立決定是否適合自己,若需要應諮詢專業建議。本行及其委任之流通量提供者可能是結構性產品的唯一市場參與者,而結構性產品的二級市場可能有限。謹請注意,牛熊證設有強制收回機制,因此有可能提早終止,在此情況下(i)N類牛熊證投資者會損失於牛熊證的全部投資;而(ii)R類牛熊證之剩餘價值則可能為零。界內證在市場是全新的結構性產品,現時在香港交易所並無類似上市產品可作比較。界內證具備有別於標準的特徵,其條款及定價或較其他標準權證複雜,其最大潛在回報為固定及設有上限。界內證價格變動可能與其掛鈎資產的價格變動不成比例或呈相反方向。

作者為金管局及證監會持牌人士,並無就結構性產品或相關資產持有任何直接或間接權益。
Sign up to our newsletter

Stay abreast of the trends with the latest investment insight and market updates.

Latest article

(Available in Chinese only)
Back to Intrady newsletters

Important Risk Warning

The structured products are not collateralized. If the issuer is insolvent or defaults, investors may not recover part or all of the amount due.

Structured products are complex products. Investors should exercise caution in relation to them. The price of the structured products may fall in value as rapidly as it may rise and investors may sustain a total or substantial loss of their investment. Prospective investors should ensure that they understand the nature and risks and seek professional advice where applicable. Please also note that CBBCs have a mandatory call feature and may therefore be subject to early termination, upon which (i) investors in category N CBBCs will lose all of their investments in the CBBCs; and (ii) the residual value of category R CBBCs may be zero. Inline warrants have been newly introduced to the market and there are no similar products currently listed on the Stock Exchange of Hong Kong Limited for comparison. Inline warrants carry exotic features, and their terms and pricing may be more complicated than standard derivative warrants. Maximum potential payoff is fixed and capped. Price movement of the inline warrants may be disproportionate or opposite to the price movement of the underlying asset. Trading structured products with United States (US) underlying index may be exposed to additional risks, including (a) risks relating to difference in trading days and hours, (b) less public information about the index and such information may not be available in Chinese, (c) political and economic risks relating to the index regions (such as the US), (d) exchange rate risks, (e) possible delay in settlement, and (f) publication of index level when component shares are not trading. Click here for "Terms of Use".

Disclaimer

By viewing this website or using any information or functions of this website, you are deemed to acknowledge that you agree to the Privacy and Security, Terms of Use and Hyperlink Policy. Click here for "Disclaimer".

All data/charts are for reference purposes only.